A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency

• DOI: 10.1530/eje.0.1440013
• Publication Date: 2005-01-24T21:34:41Z
• Authors: E Schonau; F Westermann; F Rauch; A Stabrey; G Wassmer; E Keller; J Bramswig; WF Blum
• Keywords: Deoxypyridinoline; Growth velocity

To identify parameters which predict individual growth response to recombinant human GH (rhGH) therapy and combine these in a prediction model.Fifty-eight prepubertal patients with deficiency (17 females) participated this prospective multicenter trial 1 year of follow-up.Auxological measurements, status markers bone metabolism were measured at baseline 1, 3 6 months after the start rhGH treatment. Correlations height velocity during first 12 treatment (HV+12) calculated. Prediction models derived by multiple regression analysis.The model best predicted HV+12 combined following parameters: pretreatment age retardation as fraction chronological age, serum levels IGF-I, urinary deoxypyridinoline (a marker resorption) month This explained 89% variation standard deviation residuals 0.93 cm/year. Defining successful doubling velocity, had specificity 90% sensitivity 100% predicting therapeutic success.This is an accurate practicable tool GH-deficient children. It may help optimize dose adjustment contribute improved overall outcomes.